{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:17:43Z","timestamp":1788632263794,"version":"build-2803163510"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Spasticity is a velocity-dependent increase in muscle tone that has a negative effect on quality of life and hinders the ability of others to provide care. In children, most cases are caused by cerebral palsy. Traditionally, many children are treated with surgery, sometimes performed before their limbs had grown sufficiently to permit long-term success. Nonsurgical treatment comprises oral pharmacological options, but their efficacy is limited and side effects such as drowsiness and decreased short-term memory are common; nerve block procedures can cause painful dysesthesias and muscle scarring. OnabotulinumtoxinA was first approved for the treatment of pediatric lower limb spasticity in Europe in the 1990s and is now licensed for use in pediatric patients in over 80 countries worldwide, based on a large body of clinical evidence demonstrating its efficacy and safety. In 2019 the U.S. Food and Drug Administration approved onabotulinumtoxinA for the treatment of pediatric patients with upper or lower limb spasticity. This approval represents 3 decades of work to refine the dose, measurements, patient selection, and muscle selection. The availability of onabotulinumtoxinA as a treatment for pediatric spasticity can have a substantial impact on a patient\u2019s quality of life. The use of onabotulinumtoxinA in combination with orthoses and occupational\/physical therapy can postpone corrective surgery until growth is nearly complete and minimize the number of corrective surgeries.<\/jats:p>","DOI":"10.1097\/md.0000000000032363","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:01:56Z","timestamp":1690484516000},"page":"e32363","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Mark","family":"Gormley","sequence":"first","affiliation":[{"name":"Gillette Children\u2019s Specialty Healthcare, St Paul, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry G.","family":"Chambers","sequence":"additional","affiliation":[{"name":"University of California and Rady Children\u2019s Hospital San Diego, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heakyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center and New York Presbyterian Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Leon","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalina","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan\/AbbVie, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20240803","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/ijtr.2007.14.9.24579","article-title":"What is spasticity? The discussion continues.","volume":"14","author":"Ibuki","year":"2007","journal-title":"Int J Ther Rehabil"},{"key":"R3-20240803","first-page":"279175","article-title":"Clinical understanding of spasticity: implications for practice.","volume":"2014","author":"Bhimani","year":"2014","journal-title":"Rehabil Res Pract"},{"key":"R4-20240803","first-page":"8","article-title":"A report: the definition and classification of cerebral palsy April 2006.","volume":"109","author":"Rosenbaum","year":"2007","journal-title":"Dev Med Child Neurol Suppl"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(13)61835-8","article-title":"Cerebral palsy.","volume":"383","author":"Colver","year":"2014","journal-title":"Lancet"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/dmcn.12080","article-title":"An update on the prevalence of cerebral palsy: a systematic review and meta-analysis.","volume":"55","author":"Oskoui","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"R7-20240803","first-page":"53","article-title":"Spasticity in children.","volume":"7","author":"Awaad","year":"2012","journal-title":"J Taibah Univ Med Sci"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/WNL.0b013e3181cbcd2f","article-title":"Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.","volume":"74","author":"Delgado","year":"2010","journal-title":"Neurology"},{"key":"R9-20240803","first-page":"CD004552","article-title":"Intrathecal baclofen for treating spasticity in children with cerebral palsy.","volume":"2015","author":"Hasnat","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20240803","first-page":"345","article-title":"Management of spasticity in children with cerebral palsy.","volume":"24","author":"Shamsoddini","year":"2014","journal-title":"Iran J Pediatr"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2340\/16501977-2239","article-title":"Practice patterns for spasticity management with phenol neurolysis.","volume":"49","author":"Karri","year":"2017","journal-title":"J Rehabil Med"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4103\/JPN.JPN_123_17","article-title":"Phenol versus botulinum toxin A injection in ambulatory cerebral palsy spastic diplegia: a comparative study.","volume":"12","author":"Gonnade","year":"2017","journal-title":"J Pediatr Neurosci"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/(SICI)1097-4598(1997)6+<61::AID-MUS6>3.0.CO;2-H","article-title":"Traditional pharmacological treatments for spasticity. part I: local treatments.","volume":"6","author":"Gracies","year":"1997","journal-title":"Muscle Nerve Suppl"},{"key":"R14-20240803","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/toxins7051629","article-title":"Best clinical practice in botulinum toxin treatment for children with cerebral palsy.","volume":"7","author":"Strobl","year":"2015","journal-title":"Toxins (Basel)"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/10400435.1993.10132205","article-title":"Predictors of assistive technology abandonment.","volume":"5","author":"Phillips","year":"1993","journal-title":"Assist Technol"},{"key":"R16-20240803","first-page":"44","article-title":"Factors associated with assistive technology discontinuance among individuals with disabilities.","volume":"66","author":"Riemer-Reiss","year":"2000","journal-title":"J Rehabil"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1191\/0269215504cr697oa","article-title":"Occupational therapy for children with cerebral palsy: a systematic review.","volume":"18","author":"Steultjens","year":"2004","journal-title":"Clin Rehabil"},{"key":"R18-20240803","doi-asserted-by":"crossref","first-page":"15082","DOI":"10.1038\/nrdp.2015.82","article-title":"Cerebral palsy.","volume":"2","author":"Graham","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R19-20240803","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11832-010-0268-4","article-title":"Surgical correction of equinus deformity in children with cerebral palsy: a systematic review.","volume":"4","author":"Shore","year":"2010","journal-title":"J Child Orthop"},{"key":"R20-20240803","first-page":"125","article-title":"Recurrence of equinus foot deformity in cerebral palsy patients following surgery: a review.","volume":"12","author":"Koman","year":"2003","journal-title":"J South Orthop Assoc"},{"key":"R21-20240803","first-page":"1","article-title":"Lumbosacral dorsal rhizotomy for spastic cerebral palsy: a health technology assessment.","volume":"17","year":"2017","journal-title":"Ont Health Technol Assess Ser"},{"key":"R23-20240803","first-page":"e3466","article-title":"Evidence supporting selective dorsal rhizotomy for treatment of spastic cerebral palsy.","volume":"10","author":"Park","year":"2018","journal-title":"Cureus"},{"key":"R24-20240803","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0733-8635(03)00019-6","article-title":"Development of botulinum toxin therapy.","volume":"22","author":"Scott","year":"2004","journal-title":"Dermatol Clin"},{"key":"R26-20240803","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence.","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01241398-199307000-00013","article-title":"Management of cerebral palsy with botulinum-A toxin: preliminary investigation.","volume":"13","author":"Koman","year":"1993","journal-title":"J Pediatr Orthop"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01241398-199405000-00005","article-title":"Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.","volume":"14","author":"Koman","year":"1994","journal-title":"J Pediatr Orthop"},{"key":"R29-20240803","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1469-8749.1994.tb11863.x","article-title":"Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse.","volume":"36","author":"Cosgrove","year":"1994","journal-title":"Dev Med Child Neurol"},{"key":"R30-20240803","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01241398-200001000-00022","article-title":"Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial.","volume":"20","author":"Koman","year":"2000","journal-title":"J Pediatr Orthop"},{"key":"R31-20240803","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1542\/peds.108.5.1062","article-title":"Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.","volume":"108","author":"Koman","year":"2001","journal-title":"Pediatrics"},{"key":"R32-20240803","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/dmcn.12551","article-title":"International classification of functioning, disability and health core sets for children and youth with cerebral palsy: a consensus meeting.","volume":"57","author":"Schiariti","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1469-8749.1997.tb07414.x","article-title":"Development and reliability of a system to classify gross motor function in children with cerebral palsy.","volume":"39","author":"Palisano","year":"1997","journal-title":"Dev Med Child Neurol"},{"key":"R34-20240803","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1469-8749.2008.03089.x","article-title":"Content validity of the expanded and revised Gross Motor Function Classification System.","volume":"50","author":"Palisano","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"R35-20240803","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/09638280500404305","article-title":"A systematic review of the Tardieu Scale for the measurement of spasticity.","volume":"28","author":"Haugh","year":"2006","journal-title":"Disabil Rehabil"},{"key":"R36-20240803","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity.","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys Ther"},{"key":"R37-20240803","first-page":"540","article-title":"Preliminary trial of carisoprodol in multiple sclerosis.","volume":"192","author":"Ashworth","year":"1964","journal-title":"Practitioner"},{"key":"R38-20240803","first-page":"143","article-title":"A la recherche d\u2019une technique de mesure de la spasticit\u00e9 [Research on a technique for measurement of spasticity].","volume":"91","author":"Tardieu","year":"1954","journal-title":"Rev Neurol (Paris)"},{"key":"R39-20240803","first-page":"S23","article-title":"Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy.","volume":"6","author":"Boyd","year":"1999","journal-title":"Eur J Neurol"},{"key":"R40-20240803","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-8749.2003.tb00852.x","article-title":"Reliability and validity of the Observational Gait Scale in children with spastic diplegia.","volume":"45","author":"Mackey","year":"2003","journal-title":"Dev Med Child Neurol"},{"key":"R41-20240803","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01241398-200305000-00005","article-title":"Edinburgh visual gait score for use in cerebral palsy.","volume":"23","author":"Read","year":"2003","journal-title":"J Pediatr Orthop"},{"key":"R42-20240803","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1651-2227.2010.01767.x","article-title":"Botulinum toxin A treatment in toddlers with cerebral palsy.","volume":"99","author":"Tedroff","year":"2010","journal-title":"Acta Paediatr"},{"key":"R43-20240803","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1469-8749.2005.tb01215.x","article-title":"Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy.","volume":"47","author":"Ackman","year":"2005","journal-title":"Dev Med Child Neurol"},{"key":"R44-20240803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0966-6362(99)00012-0","article-title":"Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy.","volume":"10","author":"Sutherland","year":"1999","journal-title":"Gait Posture"},{"key":"R45-20240803","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01241398-199805000-00006","article-title":"Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.","volume":"18","author":"Corry","year":"1998","journal-title":"J Pediatr Orthop"},{"key":"R46-20240803","doi-asserted-by":"crossref","first-page":"e1149","DOI":"10.1542\/peds.2006-2425","article-title":"Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial.","volume":"119","author":"Russo","year":"2007","journal-title":"Pediatrics"},{"key":"R47-20240803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.apmr.2006.10.017","article-title":"Functional outcomes of intramuscular botulinum toxin type A and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial.","volume":"88","author":"Wallen","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"key":"R48-20240803","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/S0012162206000387","article-title":"Low-dose\/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy.","volume":"48","author":"Lowe","year":"2006","journal-title":"Dev Med Child Neurol"},{"key":"R49-20240803","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1067\/mpd.2000.108393","article-title":"An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy.","volume":"137","author":"Fehlings","year":"2000","journal-title":"J Pediatr"},{"key":"R50-20240803","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1469-8749.2009.03387.x","article-title":"Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: a randomized controlled trial.","volume":"52","author":"Olesch","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"R51-20240803","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3233\/NRE-210070","article-title":"Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: a randomized, placebo-controlled, phase III clinical trial.","volume":"50","author":"Dimitrova","year":"2022","journal-title":"NeuroRehabilitation"},{"key":"R52-20240803","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/NRE-210071","article-title":"Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: phase III placebo-controlled randomized trial.","volume":"49","author":"Dimitrova","year":"2021","journal-title":"NeuroRehabilitation"},{"key":"R53-20240803","first-page":"37","article-title":"Long-term safety and efficacy of open-label onabotulinumtoxinA for the treatment of lower limb spasticity in children with cerebral palsy.","volume":"61","author":"Meilahn","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"R54-20240803","first-page":"S99","article-title":"Long-term safety and efficacy of onabotulinumtoxinA for the treatment of upper limb spasticity in children with cerebral palsy: open-label extension study.","volume":"86","author":"McCusker","year":"2019","journal-title":"Ann Neurol"},{"key":"R56-20240803","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-1331.2010.03126.x","article-title":"Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement.","volume":"17","author":"Love","year":"2010","journal-title":"Eur J Neurol"},{"key":"R57-20240803","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1469-8749.2010.03686.x","article-title":"Gross muscle morphology and structure in spastic cerebral palsy: a systematic review.","volume":"52","author":"Barrett","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"R58-20240803","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2106\/JBJS.RVW.18.00153","article-title":"Sarcopenia, cerebral palsy, and botulinum toxin type A.","volume":"7","author":"Multani","year":"2019","journal-title":"JBJS Rev"},{"key":"R59-20240803","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11914-020-00561-y","article-title":"Complicated muscle-bone interactions in children with cerebral palsy.","volume":"18","author":"Modlesky","year":"2020","journal-title":"Curr Osteoporos Rep"},{"key":"R60-20240803","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jcsm.12287","article-title":"Determinants of muscle preservation in individuals with cerebral palsy across the lifespan: a narrative review of the literature.","volume":"9","author":"Verschuren","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R61-20240803","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/dmcn.12200","article-title":"Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy.","volume":"55","author":"Williams","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"R62-20240803","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/dmcn.13988","article-title":"Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: a 6-month prospective cohort study.","volume":"60","author":"Alexander","year":"2018","journal-title":"Dev Med Child Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:56:54Z","timestamp":1722736614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":58,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032363","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}